Pearl Huang

Pearl Huang is the CEO and President of Dunad Therapeutics. Previously, Pearl served as the CEO of Cygnal Therapeutics and held various executive positions at Roche, GlaxoSmithKline, Beigene Bio, Merck and Co, GSK, and DuPont Pharmaceuticals Company. Pearl's expertise lies in drug discovery, oncology, molecular biology, and portfolio management. Pearl holds a Ph.D. in Molecular Biology from Massachusetts Institute of Technology and a SB in Life Sciences from Princeton University.